Joshua B. Cohen - 06 Jan 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen
Issuer symbol
AMLX
Transactions as of
06 Jan 2022
Transactions value $
$0
Form type
4
Filing time
10 Jan 2022, 19:32:06
Next filing
06 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security $0 +4.87K +0.2% $0.00 2.49M 06 Jan 2022 Direct F1
transaction AMLX Common Stock Award $0 +75K +3.01% $0.00 2.56M 06 Jan 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -4.87K -100% $0.00* 0 06 Jan 2022 Common Stock 4.87K Direct F1
transaction AMLX Stock Option (right to buy) Award $0 +338K $0.00 338K 06 Jan 2022 Common Stock 338K $19.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
F2 The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F3 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.